VDYNE (NASDAQ: VDYNE) Receives FDA Approval for TRIVITA1 IDE Clinical Trial
Market Overview VDYNE (NASDAQ: VDYNE), a company focused on advancing next-generation transcatheter valve replacement technology, has reached a significant milestone with the U.S. Food and Drug Administration (FDA) approval of its Investigational Device Exemption (IDE) application. This approval allows VDYNE to initiate pivotal clinical trials for its innovative Transcatheter Tricuspid Valve Replacement (TTVR) system, aiming to address severe tricuspid regurgitation. The market for tricuspid valve treatments remains underserved with approximately…
